Core Viewpoint - A-share listed company Chengchang Technology (001270) faces unprecedented operational challenges and market pressure, leading to a formal delisting risk warning and a change in stock abbreviation to "*ST Chengchang" starting April 24, 2025 [1] Financial Performance - In 2024, Chengchang Technology reported an operating revenue of 212 million yuan, a year-on-year decline of 26.38% [1] - The company recorded a net profit attributable to shareholders of -31.12 million yuan, showing a significant year-on-year decrease [1] - After excluding non-recurring gains and losses, the net profit loss reached 43.61 million yuan [1] Business Challenges - The company's main business involves the research, production, sales, and technical services of microwave and millimeter-wave analog phased array T/R chips [1] - The sharp decline in performance reflects various challenges faced during operations, including long production cycles of downstream equipment and delays in project approvals, which severely impacted revenue recognition and profit realization [1] R&D and Financial Management - Chengchang Technology has been increasing its R&D investment to maintain technological leadership and market competitiveness, which has negatively impacted revenue and net profit [2] - The increase in credit impairment losses on accounts receivable has also significantly contributed to the decline in net profit [2] Strategic Response - In response to the delisting risk warning, Chengchang Technology plans to take proactive measures to address its operational difficulties [2] - The company aims to enhance product quality and technical standards while strengthening communication and cooperation with customers to accelerate product delivery and acceptance [2] - Additionally, the company will focus on improving internal management and risk control, optimizing accounts receivable management, and exploring new business areas and market opportunities for profit growth [2]

返利科技（600228）公告，因公司股票将被实施退市风险警示，公司股票将于2025年4月25日停牌一 天，并于2025年4月28日起被实施退市风险警示，股票简称变更为*ST返利。实施退市风险警示的起始 日为2025年4月28日。 ...

绿康生化（002868）公告，预计2024年期末净资产为-2300万元，归属上市公司股东的净利润为亏损 4.35亿元–3.85亿元。根据《深圳证券交易所股票上市规则》规定，公司股票交易将在2024年年度报告披 露后被实施退市风险警示(*ST)。此外，公司股票也可能被实施其他风险警示(ST)，因公司最近连续三 个会计年度扣除非经常性损益前后净利润均为负值，且最近一年审计报告显示公司持续经营能力存在不 确定性。 ...

凌云B股公告，公司2024年度经审计的利润总额、净利润、扣除非经常性损益后的净利润均为负值，且 营业收入低于3亿元。根据《上海证券交易所股票上市规则》9.3.2条(一)项规定，公司股票将被实施退 市风险警示，证券简称将变更为"*ST凌云B"，实施起始日为2025年4月25日。公司股票将于2025年4月 24日停牌1天，2025年4月25日开市起复牌并实施退市风险警示。 ...

Core Viewpoint - Chengchang Technology has announced a negative net profit for the fiscal year 2024, leading to a one-day suspension of its stock and a subsequent risk warning for delisting due to insufficient revenue and profit metrics [2][4]. Group 1: Financial Performance - For the fiscal year 2024, Chengchang Technology reported a total revenue of 211.5 million yuan, a year-on-year decrease of 26% [4]. - The net profit attributable to shareholders was -31.12 million yuan, with a net loss of 43.61 million yuan after excluding non-recurring gains and losses [4]. - In the first quarter of 2025, the company achieved a turnaround with a revenue of 92.01 million yuan, an increase of 72.23 million yuan compared to the same period last year, and a net profit of 29.82 million yuan [4][5]. Group 2: Stock Market Impact - Due to the negative net profit and revenue below 300 million yuan, Chengchang Technology's stock will be marked with a "*ST" designation, indicating a risk of delisting [2][4]. - The stock will be subject to a daily price fluctuation limit of 5% following the risk warning [2]. Group 3: Operational Challenges - The company cited delays in project approvals and delivery as factors contributing to the lower-than-expected revenue and profit [4]. - Chengchang Technology is actively investing in research and development across multiple fields, which has impacted its revenue and net profit [4]. Group 4: Company Background - Established in November 2010, Chengchang Technology specializes in the research, production, and sales of microwave and millimeter-wave phased array T/R chips, being one of the few companies in China to provide complete solutions for these chips [5].

重要内容提示： 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 ● 公司预计更正后2024年年度实现利润总额为-180万元到-120万元；公司预计2024年年度实现归属于母 公司所有者的净利润为-500万元到-400万元；公司预计2024年年度实现归属于母公司所有者的扣除非经 常性损益的净利润为-550万元到-450万元。 ● 公司预计2024年年度实现营业收入1.1亿元到1.2亿元，扣除与主营业务无关的业务收入和不具备商业 实质的收入后实现营业收入1.05亿元到1.15亿，低于3亿元。 ● 根据《上海证券交易所股票上市规则》9.3.2条（一）规定的情形："最近一个会计年度经审计的利润 总额、净利润或者扣除非经常性损益后的净利润孰低者为负值且营业收入低于3亿元，或追溯重述后最 近一个会计年度利润总额、净利润或者扣除非经常性损益后的净利润孰低者为负值且营业收入低于3亿 元"，公司股票可能被实施退市风险警示，敬请广大投资者注意投资风险，理性投资。 ● 业绩预告的具体适用情形：公司预计2024年年度利润总额、净利润、扣除非经常性损益 ...

重要风险提示： 1、公司于2025年1月18日在《中国证券报》《证券时报》和巨潮资讯网（www.cninfo.com.cn）披露了 《2024年度业绩预告》（公告编号：2025-003）。经公司财务部门初步测算（未经审计），预计公司 2024年度归属于上市公司股东的净利润为负值，且扣除后营业收入为14,000万元至18,000万元。根据 《深圳证券交易所股票上市规则》的相关规定，公司股票交易将在2024年年度报告披露后可能被实施退 市风险警示（股票简称前冠以"*ST"字样）。敬请广大投资者注意投资风险。 2、股票异常波动风险 公司分别于2025年4月15日、2025年4月17日披露《股票交易异常波动及风险提示性公告》（公告编号： 2025-015、2025-016）。公司股票（证券简称：双成药业，证券代码：002693）收盘价格涨幅偏离值累 计达到深圳证券交易所的有关规定属于股票交易异常波动情况。近期，公司股票交易价格发生较大波 动，敬请广大投资者注意二级市场交易风险，理性决策，审慎投资。 登录新浪财经APP 搜索【信披】查看更多考评等级 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载 ...

Core Viewpoint - Nanhua Biological (000504.SZ) significantly revised its 2024 annual performance forecast from a profit of 12.5 million to 15.5 million yuan to a loss of 19 million to 21 million yuan, triggering delisting risk warning conditions [1] Group 1: Performance Revision - The company’s 2024 net profit and net profit after deducting non-recurring gains and losses are both negative, with operating revenue below 300 million yuan, leading to a "*ST" designation for its stock [1] - The revision was attributed to return risks primarily related to the sales of the company's beauty products, as prior profit announcements were made before a comprehensive audit [5] Group 2: Business Transformation - Nanhua Biological has been transitioning towards beauty and anti-aging sectors, which are key areas of its recent business strategy, while previously being involved in real estate, media, biomedicine, and energy-saving industries [5] - The company has faced delisting risk warnings multiple times in the past due to consecutive years of losses, specifically in 2010, 2013, 2016, and 2019 [5] Group 3: Management and Control - The frequent changes in the company's business focus are linked to changes in its controlling shareholders, although the company asserts that there are no internal management issues or control deficiencies [5]

金十数据4月22日讯，双成药业公告称，公司股票交易价格连续两个交易日收盘价格跌幅偏离值累计超 过20%，属于股票交易异常波动情况。经核实，公司前期披露的信息不存在需要更正、补充之处，近期 公司经营情况及内外部经营环境未发生重大变化，公司及控股股东、实际控制人不存在关于公司的应披 露而未披露的重大事项。公司提醒投资者注意二级市场交易风险，理性决策，审慎投资。同时，公司预 计2024年度归属于上市公司股东的净利润为负值，且扣除后营业收入为1.4亿元至1.8亿元，可能被实施 退市风险警示。 双成药业：目前经营情况正常 未发现应披露而未披露的重大事项 ...

4月22日，南华生物开盘即一字跌停，报8.11元，总市值为26.76亿元。 | 9.07 | | | | --- | --- | --- | | 9.01 | | | | 8.95 | | | | 8,88 | | | | 8.82 | | | | 8.75 | | | | 8.69 | | | | 8.62 | | | | 8,56 | | | | 8.50 | | | | 8.43 | | | | 8,37 | | | | 8.30 | | | | 8.24 | | | | 8.17 | | | | 8,11 | | | | 04/22 | 11:00 | 11:30 | 这一股价变动主要源于公司前一日晚间发布的业绩预告修正公告，即2024年归属于上市公司股东的净利润由预盈1250万–1550万元修正为预亏1900万–2100万 元。 业绩大变脸 | 项目 | 本报告期 | | 上年同期 | 是否修 | | --- | --- | --- | --- | --- | | | 原预计 | 最新预计 | | 正 | | 归属于上市公司 | 盈利: 1,250 万元 | 亏损:1,900 万 元 -2,100 ...